Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + Cadonilimab in HER2+ Urothelial Carcinoma
NCT06178601Phase 2Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, cadonilimab in urothelial carcinoma (UC), sponsored by Shanxi Cancer Hospital. Started Aug 2023; status: recruiting.
02
Drugs
disitamab vedotincadonilimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06178601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178601.